Specifically, we analyzed pretreatment IGF2 levels in the plasma of a cohort consisting of 68 patients with cancer enrolled in a basket trial for anti–PD-1 treatment, encompassing individuals diagnosed with BRCA, COAD, and LUAD. This evidence concerns the gene IGF2 and cancer.